Real-world pharmacovigilance assessment of meropenem-associated adverse events: age stratification and time-to-onset analysis using FAERS Authors: Xiaobin Luo, Yali Zhong, Yong Zou, Chenghao Yang Published: 2026 ABSTRACT BackgroundMeropenem is a broad-spectrum carbapenem antibiotic widely used for severe infections; however, its real-world adverse event profile and age-stratified pharmacovigilance signals remain insufficiently characterized. This study aimed to evaluate signals of meropenem-associated adverse events using the FDA Adverse Event Reporting System (FAERS).MethodsFAERS reports from 2004 Q1 to 2025 Q4 were extracted. Reports listing meropenem as the primary suspect drug were included after standardization and deduplication. Disproportionality analyses were performed at the Preferred Term (PT) level using the reporting odds ratio, proportional reporting ratio, empirical Bayes geometric mean, and information component, with a Bonferroni correction applied to PRR chi-square P-values for multiple PT-level comparisons. Reports were stratified into five age groups: < 18, 18–39, 40–59, 60–79, and ≥80 years. Age-, sex-, seriousness-, fatality-, and time-to-onset stratified analyses were conducted. A healthcare professional (HCP)-only subset analysis was performed using the same statistical framework.ResultsA total of 5,018 meropenem primary suspect drug-event records were identified, corresponding to 4,431 deduplicated report-level cases after merging FAERS DEMO, DRUG, and REAC tables. Overall, 254 PT-level signals remained significant after four-algorithm screening and Bonferroni correction. These signals were mainly distributed across infections and infestations, investigations, skin and subcutaneous tissue disorders, blood and lymphatic system disorders, and hepatobiliary disorders. Frequently detected PTs included pyrexia, acute kidney injury, pancytopenia, thrombocytopenia, septic shock, seizure, DRESS, multiple organ dysfunction syndrome, and sepsis. Age-stratified analysis showed a heterogeneous distribution of signals across age groups, with higher numbers of reports and signals observed in the 40–79-year age group. The proportion of reported serious outcomes increased across age strata, exceeding 85% among patients aged ≥40 years. Median time-to-onset was 5 days, and the Weibull shape parameter (β = 0.72) suggested an early-reporting pattern of events. HCP-only analysis demonstrated consistent signal patterns compared with the primary analysis at the PT level.ConclusionsMeropenem-associated adverse event signals involved multiple organ systems and demonstrated heterogeneous distribution across age groups. Early-onset clustering was observed for several key signals. These findings represent FAERS-based disproportionality signals rather than causal associations and require further sclinical validation. Introduction Meropenem is a broad-spectrum carbapenem antibiotic with potent antimicrobial activity against Gram-negative and Gram-positive bacteria, as well as anaerobic organisms. It plays an important role in the treatment of multidrug-resistant Gram-negative infections. It is widely used for complicated skin and soft tissue infections (cSSTIs), complicated intra-abdominal infections, hospital-acquired pneumonia, and other serious infections caused by resistant pathogens (1). In clinical practice, carbapenems are considered key therapeutic options for severe infections requiring broad-spectrum coverage, and meropenem has demonstrated favorable efficacy and tolerability in cSSTIs and secondary peritonitis (1, 2). It is also frequently used in hospital-acquired infections and intensive care unit (ICU) settings, where it is among the most commonly prescribed broad-spectrum antibiotics in acute care hospitals (1). In surgical and perioperative settings, meropenem is commonly used for early postoperative infections, complicated infections, and empirical therapy in critically ill patients. It has also been reported to have potential value in biofilm-associated surgical site infections (3). Due to its ability to cross the blood-brain barrier, meropenem reaches high concentrations in cerebrospinal fluid and is effective against bacterial meningitis (4). Clinical applications have also been reported in central nervous system infections caused by resistant organisms, including carbapenem-resistant Acinetobacter baumannii (5). In addition, meropenem is widely used for pediatric bacterial meningitis and multidrug-resistant Gram-negative infections due to its relatively low risk of seizures and favorable safety profile (6, 7). Although meropenem is generally well-tolerated, its clinical use is complicated by multiple factors. In critically ill patients, altered renal function, volume of distribution, and inflammatory status may affect attainment of pharmacokinetic/pharmacodynamic (PK/PD) targets, potentially influencing drug exposure (8). In addition, broad-spectrum antibiotics may disrupt gut microbiota and vitamin K metabolism and have been associated with coagulation abnormalities in specific populations, such as patients with severe burns (9). Emerging evidence and case reports suggested that meropenem may be associated with neurotoxicity, renal dysfunction, hematologic abnormalities, hypersensitivity reactions, and other adverse events (10–15). Among these, neurotoxicity may manifest as seizures, encephalopathy, or disturbances of consciousness, whereas hematologic adverse events may present as thrombocytopenia, neutropenia, or pancytopenia. These adverse reactions may be particularly pronounced in critically ill patients, those with impaired renal function, and individuals receiving multiple concomitant medications. Age is an important determinant of antimicrobial safety. As the population ages, the proportion of older adults in surgical and ICU settings continues to increase. Older patients are more likely to experience physiological decline, reduced renal function, comorbidities, and polypharmacy, which may increase vulnerability to drug-related adverse events (16). At the same time, older adults are more frequently exposed to meropenem due to higher infection severity and may therefore require closer safety monitoring during treatment (17). However, systematic evidence on age-related differences in the safety profiles of meropenem remains limited. Existing studies on meropenem safety have primarily been derived from FAERS-based signal detection, randomized controlled trials, and observational studies (18–20). Although these studies provided important insights, they are limited by the underrepresentation of elderly populations, the limited detection of rare adverse events, and the insufficient characterization of temporal patterns. In particular, previous studies have largely focused on overall adverse event profiles. In contrast, comparatively few have systematically evaluated the real-world distribution patterns of meropenem-associated adverse events across age strata, system-organ class classifications, and time-to-onset characteristics. Although randomized controlled trials (RCTs) are the gold standard for evaluating drug efficacy and safety, they are limited in detecting rare or delayed adverse events due to strict eligibility criteria, limited sample sizes, and short follow-up durations. Furthermore, elderly and critically ill patients with multimorbidity and polypharmacy are often underrepresented in clinical trials, despite being major recipients of meropenem therapy. Consequently, real-world patterns of drug exposure and adverse event profiles in these populations may not be fully captured in clinical trials. Large-scale pharmacovigilance databases based on spontaneous reporting systems provide an important approach to addressing these evidence gaps. The United States Food and Drug Administration Adverse Event Reporting System (FAERS), characterized by broad population coverage and diverse reporting sources, facilitates the identification of potential safety signals that may not be fully captured in clinical trials and serves as an important complement to conventional clinical research. Within pharmacovigilance research, disproportionality analysis enables the exploration of statistical associations between specific drugs and adverse events using real-world reports, whereas time-to-onset (TTO) analysis and Weibull distribution models further characterize the temporal patterns of adverse event occurrence, thereby providing complementary evidence for identifying an early exposure monitoring window and optimizing clinical risk management strategies. Accordingly, the present study systematically evaluated the real-world safety characteristics of meropenem-associated adverse events using the FAERS database, with particular emphasis on signal distribution across age groups, system organ class characteristics, serious outcomes, and temporal dynamics. By integrating age-stratified disproportionality analysis with TTO and Weibull-based time-dynamic modeling, this study aimed to provide a comprehensive real-world pharmacovigilance profile of meropenem. Materials and methods Data source and study design This retrospective pharmacovigilance study was conducted using the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Publicly available FAERS reports from the first quarter of 2004 to the fourth quarter of 2025 were included. The FAERS database primarily comprises the demographic information table (DEMO), drug information table (DRUG), adverse reaction table (REAC), therapy start and end date table (THER), report source table (RPSR), and outcome table (OUTC). Reports were used as the fundamental analytical unit, and data linkage across tables was performed using the unique report identifier (PRIMARYID). A total of 5,018 meropenem-related drug–event records were extracted from the DRUG table where meropenem was identified as the primary suspect (ROLE_COD = PS). These records represent Preferred Term (PT)-level drug–event pairs, as a single FAERS report may contain multiple adverse events. Each PT was counted once per report to avoid duplication. This dataset was used for overall signal detection and sex-stratified analyses based on report-level demographic information linked via PRIMARYID. Subsequently, the DEMO, DRUG, and REAC tables were merged using PRIMARYID and deduplicated at the report level, resulting in 4,431 unique meropenem-associated reports for the primary analysis. Based on this primary cohort, three analytical subsets were derived: (1) Healthcare professional (HCP) sensitivity cohort: 3,184 reports submitted by healthcare professionals (e.g., physicians, pharmacists, and other clinical reporters) were included for sensitivity analysis to assess the robustness of the primary findings. (2) Age-stratified cohort: Among the 4,431 deduplicated reports, cases with complete age information were selected, yielding 3,832 reports for demographic characterization, outcome analysis, and age-stratified analyses. (3) Time-to-onset (TTO) cohort: A total of 1,371 reports containing complete treatment initiation and adverse event onset dates were included for TTO and Weibull parameter analyses. All analyses were conducted at predefined analytical levels, with PT-level analyses used for disproportionality signal detection and report-level analyses used for demographic, stratified, and time-to-onset assessments. The data screening workflow is presented in Figure 1. Study workflow for FAERS-based analysis of meropenem adverse event signals. The workflow shows data extraction, deduplication, identification of meropenem primary suspect reports, construction of the report-level analytical cohort, and subsequent analyses, including overall signal detection, sex-stratified analysis, age-stratified analysis, outcome analysis, healthcare professional-only sensitivity analysis, time-to-onset analysis, and Weibull parameter analysis. FAERS, FDA Adverse Event Reporting System. Drug and adverse event definitions The target drug was meropenem. Meropenem-associated reports were identified in the DRUG table through standardized drug name normalization, and only reports in which meropenem was designated as the primary suspect drug were included to improve the specificity of drug–event association analyses. Adverse events were extracted using preferred terms (PTs) recorded in the REAC table and further categorized into the system organ class (SOC) hierarchy. Both PT and SOC terminology followed the Medical Dictionary for Regulatory Activities (MedDRA) classification system. To minimize the impact of duplicate reporting, report-level analyses were conducted using unique PRIMARYID values as the unit of analysis. For PT-level analyses, repeated occurrences of identical PTs within the same report were counted only once. Age stratification, outcome definitions, and sensitivity analysis Based on reported ages, cases were classified into five age groups: 0–17.99, 18–39.99, 40–59.99, 60–79.99, and ≥80 years. A total of 3,832 reports contained valid age information and were included in age-stratified analyses. Outcome information was extracted from the OUTC table. Serious outcomes included death, hospitalization, life-threatening conditions, disability, and other medically serious events. Death was additionally analyzed separately as an indicator of fatal burden. To evaluate the influence of reporting source on the primary findings, an additional sensitivity analysis restricted to healthcare professional (HCP) reports was performed. This HCP-only cohort comprised 3,184 reports. Healthcare professional (HCP) reports were identified using the reporter occupation variable OCCP_COD in the FAERS DEMO table. Reports with OCCP_COD coded as MD (physician), PH (pharmacist), HP (health professional), or OT (other health professional) were classified as HCP reports. Reports coded as CN (consumer) or LW (lawyer), as well as reports with missing OCCP_COD, were excluded from the HCP-only sensitivity analysis. This subset was used to assess the robustness of the primary disproportionality findings by reducing potential reporting bias associated with non-professional reporting sources. Disproportionality analysis and signal detection criteria This study employed both frequentist and Bayesian disproportionality methods to detect potential drug–adverse event signals, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the empirical Bayes geometric mean (EBGM), and the information component (IC). Disproportionality analyses were conducted at the drug–Preferred Term (PT) level using report-level data. For each drug–PT pair, a 2 × 2 contingency table was constructed, based on unique FAERS reports (PRIMARYID), where a represented reports containing both meropenem and the target PT, b represented reports containing meropenem with other PTs, c represented reports containing the target PT with other drugs, and d represented reports containing neither meropenem nor the target PT. Signal detection was based on established criteria applied to the contingency table cell counts and derived statistics. PTs representing non-adverse-event concepts, including indications, medication errors, drug interactions, resistance-related terms, therapeutic failure, and product quality issues, were excluded before final signal interpretation. For the frequentist methods, a signal was considered present when a ≥ 3 and the lower limit of the 95% confidence interval (CI) of the ROR exceeded 1, and when a ≥ 3, PRR ≥ 2 and χ2 ≥ 4. For Bayesian methods, signals were considered positive when a ≥ 3 and EBGM05>2, and when a ≥ 3 and the lower limit of the information component 95% credibility interval (IC025) exceeded 0. PTs fulfilling all four predefined signal detection criteria (ROR, PRR, EBGM, and IC) were classified as positive signals. To reduce the risk of false-positive findings from multiple comparisons across PTs, a Bonferroni correction was applied to the P-values from PRR chi-square statistics for all 1,734 initially identified PTs, providing a conservative adjustment for PT-level comparisons. PTs with Bonferroni-corrected P values < 0.05 were considered statistically significant. Bayesian shrinkage-based measures, including EBGM and IC, were interpreted using their predefined lower-bound thresholds and were not subjected to additional Bonferroni correction. For age-stratified disproportionality analyses, separate 2 × 2 contingency tables were constructed within each age stratum using all FAERS reports from the corresponding age group as the reference population. All statistical formulas and thresholds are provided in Supplementary Table 1. The complete PT-level signal output, including the four-cell contingency table values (a, b, c, and d) and corresponding disproportionality metrics, is provided in Supplementary Table 3. For visualization of age-stratified signal distributions, PT-level and SOC-level counts across age groups were transformed into row-wise Z scores. Positive Z-score values indicate relatively enriched reporting within a given age group compared with the overall age distribution of the same PT or SOC, whereas negative values indicate relative underrepresentation. These Z-score transformations were used solely for visualization purposes and do not represent effect sizes or disproportionality estimates. For age-stratified analyses, a Bonferroni correction was applied separately within each age stratum, based on the number of PTs tested in that stratum. Time-to-onset and Weibull parameter analysis Time-to-onset (TTO) was defined as the interval between the reported date of adverse event occurrence and the initiation date of meropenem therapy. Only reports containing both valid treatment initiation dates and adverse event onset dates, with non-negative TTO values, were included. A total of 1,371 eligible reports were included in the overall TTO analysis. TTO was summarized using the median and interquartile range (IQR). Weibull distribution modeling was performed to characterize temporal reporting patterns within this subset. In addition to the overall TTO analysis, exploratory SOC-level TTO analyses were conducted using report–SOC pairs among reports with available date information. Each report could contribute to more than one SOC if adverse events from different SOC categories were recorded. SOCs with at least 20 report-SOC pairs were summarized using median TTO, IQR, and the proportions of reports occurring within 3, 7, and 10 days. Weibull parameters were estimated for SOCs with at least 30 report–SOC pairs. For Weibull fitting, TTO values of 0 day were treated as 0.5 days to allow continuous distribution modeling. Within the Weibull model, the scale parameter (α) reflects the temporal scale of reporting, whereas the shape parameter (β) characterizes the temporal reporting pattern. A β value less than 1 was interpreted as an early-reporting pattern, β approximately equal to 1 as a random-compatible or indeterminate reporting pattern, and β greater than 1 as a delayed-reporting pattern. Given the incomplete availability of date information in FAERS, both overall and SOC-level TTO analyses were interpreted as descriptive temporal reporting patterns rather than representative estimates for all meropenem-associated reports. Results Data selection workflow and construction of the analytical cohort After drug name standardization and restriction to reports in which meropenem was designated as the primary suspect drug, 5,018 PT-level meropenem- related drug-event pairs were identified and used for the overall disproportionality analysis. Because a single FAERS report may contain more than one adverse event PT, these PT-level drug–event pairs corresponded to 4,431 unique meropenem-associated reports after merging the DEMO, DRUG, and REAC tables by PRIMARYID and deduplicating at the report level. All report-level analyses were subsequently conducted using analytical subsets derived from these 4,431 deduplicated reports. Specifically, demographic characterization, outcome analysis, and age-stratified analyses included 3,832 reports with complete age information; the HCP-only sensitivity analysis included 3,184 reports submitted by healthcare professionals according to the predefined FAERS reporter-type coding scheme; and time-to-onset (TTO) and Weibull parameter analyses included 1,371 reports with complete treatment initiation and adverse event onset date information. Age-stratified demographic and reporting characteristics Among the 3,832 reports with valid age information, the 60–79-year age group accounted for the largest number of reports (n = 1,311), followed by the 40–59-year group (n = 878), the < 18-year group (n = 677), the 18–39-year group (n = 502), and the ≥80-year group (n = 464; Table 1). Table 1Demographic and clinical characteristics of meropenem-related adverse event reports across age groups in the FAERS database.Variable<18 (n = 677)18–39 (n = 502)40–59 (n = 878)60–79 (n = 1,311)≥80 (n = 464)GenderFemale293 (43.3%)277 (55.2%)383 (43.6%)525 (40.0%)206 (44.4%)Male372 (54.9%)219 (43.6%)480 (54.7%)763 (58.2%)246 (53.0%)Missing12 (1.8%)6 (1.2%)15 (1.7%)23 (1.8%)12 (2.6%)Weight<50 kg168 (24.8%)32 (6.4%)21 (2.4%)51 (3.9%)28 (6.0%)>100 kg2 (0.3%)10 (2.0%)46 (5.2%)40 (3.1%)10 (2.2%)≥50 and < 100 kg49 (7.2%)86 (17.1%)184 (21.0%)323 (24.6%)134 (28.9%)Missing458 (67.7%)374 (74.5%)627 (71.4%)897 (68.4%)292 (62.9%)Reporter typeConsumer17 (2.5%)19 (3.8%)39 (4.4%)62 (4.7%)19 (4.1%)Health professional128 (18.9%)133 (26.5%)199 (22.7%)242 (18.5%)79 (17.0%)Missing219 (32.3%)110 (21.9%)160 (18.2%)313 (23.9%)92 (19.8%)Pharmacist59 (8.7%)51 (10.2%)153 (17.4%)241 (18.4%)125 (26.9%)Physician254 (37.5%)189 (37.6%)327 (37.2%)453 (34.6%)149 (32.1%)OutcomeDeath81 (12.0%)63 (12.5%)152 (17.3%)237 (18.1%)83 (17.9%)Disability5 (0.7%)1 (0.2%)5 (0.6%)16 (1.2%)1 (0.2%)Hospitalization177 (26.1%)138 (27.5%)277 (31.5%)407 (31.0%)157 (33.8%)Life-threatening61 (9.0%)58 (11.6%)111 (12.6%)106 (8.1%)39 (8.4%)Other353 (52.1%)242 (48.2%)333 (37.9%)545 (41.6%)184 (39.7%)Non-serious/seriousNo190 (28.1%)95 (18.9%)103 (11.7%)175 (13.3%)67 (14.4%)Yes487 (71.9%)407 (81.1%)775 (88.3%)1,136 (86.7%)397 (85.6%)Non-fatal/fatalNo596 (88.0%)439 (87.5%)726 (82.7%)1,074 (81.9%)381 (82.1%)Yes81 (12.0%)63 (12.5%)152 (17.3%)237 (18.1%)83 (17.9%)Year20046 (0.9%)3 (0.6%)6 (0.7%)8 (0.6%)2 (0.4%)20056 (0.9%)2 (0.4%)2 (0.2%)6 (0.5%)1 (0.2%)20065 (0.7%)1 (0.2%)8 (0.9%)11 (0.8%)3 (0.6%)200713 (1.9%)8 (1.6%)8 (0.9%)10 (0.8%)8 (1.7%)200814 (2.1%)5 (1.0%)11 (1.3%)14 (1.1%)11 (2.4%)200926 (3.8%)5 (1.0%)6 (0.7%)9 (0.7%)1 (0.2%)201013 (1.9%)10 (2.0%)8 (0.9%)22 (1.7%)5 (1.1%)201160 (8.9%)29 (5.8%)22 (2.5%)37 (2.8%)11 (2.4%)201250 (7.4%)23 (4.6%)22 (2.5%)46 (3.5%)20 (4.3%)201320 (3.0%)9 (1.8%)21 (2.4%)28 (2.1%)5 (1.1%)201422 (3.2%)14 (2.8%)17 (1.9%)35 (2.7%)14 (3.0%)201529 (4.3%)22 (4.4%)35 (4.0%)64 (4.9%)12 (2.6%)201646 (6.8%)20 (4.0%)22 (2.5%)51 (3.9%)11 (2.4%)201734 (5.0%)13 (2.6%)56 (6.4%)76 (5.8%)25 (5.4%)201826 (3.8%)34 (6.8%)64 (7.3%)88 (6.7%)39 (8.4%)201934 (5.0%)39 (7.8%)55 (6.3%)96 (7.3%)38 (8.2%)202041 (6.1%)41 (8.2%)77 (8.8%)91 (6.9%)31 (6.7%)202139 (5.8%)40 (8.0%)80 (9.1%)117 (8.9%)33 (7.1%)202227 (4.0%)43 (8.6%)70 (8.0%)93 (7.1%)29 (6.2%)202343 (6.4%)35 (7.0%)69 (7.9%)103 (7.9%)43 (9.3%)202458 (8.6%)56 (11.2%)103 (11.7%)147 (11.2%)55 (11.9%)202565 (9.6%)50 (10.0%)116 (13.2%)159 (12.1%)67 (14.4%) Demographic and clinical characteristics of meropenem-related adverse event reports across age groups in the FAERS database. Regarding sex distribution, male reports predominated in most age groups except for the 18–39-year group, in which females accounted for a slightly higher proportion. Specifically, males represented 54.9% of reports in the < 18-year group, 54.7% in the 40–59-year group, 58.2% in the 60–79-year group, and 53.0% in the ≥80-year group, whereas females accounted for 55.2% of reports in the 18–39-year group. With respect to reporter type, physician reports constituted a relatively high proportion across all age groups, ranging from 32.1 to 37.6%. Pharmacist reporting generally increased with age, reaching 26.9% in the ≥80-year group. Reports submitted by healthcare professionals were most common in the 18–39-year group (26.5%). Regarding outcomes, higher proportions of reports of serious outcomes were observed in older age groups. Serious outcomes accounted for 71.9% of reports in the < 18-year group, 81.1% in the 18–39-year group, 88.3% in the 40–59-year group, 86.7% in the 60–79-year group, and 85.6% in the ≥80-year group. The proportions of fatal outcomes were 12.0% and 12.5% in the < 18 and 18–39-year groups, respectively, and were 17.3%, 18.1%, and 17.9% in the 40–59, 60–79, and ≥80-year groups, respectively. Visualized age-related patterns of serious and fatal outcomes are presented in Figures 2A, B. Outcome reporting patterns and HCP-only sensitivity analysis of meropenem-associated adverse event reports. (A) Age-stratified fatal outcome reporting proportions. (B) Age-stratified serious outcome reporting proportions. (C) SOC-level fatal outcome reporting burden. (D) Selected PTs co-reported with fatal outcomes. (E) Comparison of the 20 most frequently reported PTs between the primary analysis and the HCP-only sensitivity analysis. (F) PT-level reporting correlation between the primary analysis and the HCP-only sensitivity analysis. Each point represents a PT. Axes are displayed on a log10 scale. Red points indicate the most frequently reported PTs (Top 30), and blue points represent all other PTs. HCP, healthcare professional; PT, preferred term; SOC, system organ class. Overall meropenem-associated adverse event signals A total of 1,734 unique PTs were initially identified. After exclusion of 875 PTs with fewer than three reports (a < 3) and 30 PTs (Supplementary Table 5) representing non-adverse-event concepts, 829 PTs remained for signal evaluation. Among these, 362 PTs met all four predefined signal-detection criteria (ROR, PRR, EBGM, and IC). Following Bonferroni correction, 254 PTs remained statistically significant and were retained as the final meropenem-associated adverse event signals (Table 2). At the SOC level, signals were primarily concentrated in infections and infestations, investigations, skin and subcutaneous tissue disorders, nervous system disorders, blood and lymphatic system disorders, and respiratory disorders (Figure 3A). Table 2Overall positive adverse event signals associated with meropenem identified using four pharmacovigilance algorithms and Bonferroni correction.SOCPTCasesROR (95%CI)PRR (χ2)EBGM (EBGM05)IC (IC025)P-valueBonferroni-adjusted P-valueVascular disordersShock497.75 (5.86–10.26)7.73 (286.93)7.72 (5.83)2.95 (2.36)6.7E-631.2E-59Cyanosis255.69 (3.84–8.42)5.68 (96.29)5.67 (3.83)2.5 (1.7)1.2E-112.0E-08Haemodynamic instability*136.36 (3.69–10.95)6.35 (58.54)6.34 (3.68)2.67 (1.43)2.7E-074.7E-04Skin and subcutaneous tissue disordersDrug reaction with eosinophilia and systemic symptoms17020.39 (17.53–23.73)20.21 (3,092.34)20.13 (17.3)4.33 (3.96)0.0E+000.0E+00Rash maculo-papular10416.7 (13.77–20.26)16.61 (1,521.11)16.56 (13.65)4.05 (3.57)0.0E+000.0E+00Toxic epidermal necrolysis8319.73 (15.89–24.48)19.64 (1,462.35)19.56 (15.76)4.29 (3.69)3.5E-756.0E-72Drug eruption7715.79 (12.61–19.75)15.72 (1,058.15)15.67 (12.52)3.97 (3.39)7.2E-631.2E-59Blister623.82 (2.97–4.9)3.81 (128.39)3.81 (2.97)1.93 (1.5)3.8E-296.5E-26Rash erythematous614.75 (3.7–6.11)4.74 (180.07)4.74 (3.68)2.24 (1.79)3.0E-405.3E-37Stevens–Johnson syndrome579.31 (7.18–12.08)9.28 (420.6)9.27 (7.14)3.21 (2.64)1.1E-911.9E-88Toxic skin eruption5318.55 (14.16–24.31)18.5 (874.11)18.43 (14.07)4.2 (3.41)2.4E-474.2E-44Acute generalized exanthematous pustulosis4922.2 (16.76–29.4)22.14 (984.39)22.04 (16.64)4.46 (3.55)1.6E-472.8E-44Dermatitis bullous3215.45 (10.92–21.87)15.43 (430.36)15.38 (10.87)3.94 (2.92)7.2E-271.2E-23Purpura*228.77 (5.77–13.33)8.76 (151.03)8.75 (5.76)3.13 (2.11)5.1E-148.8E-11Dermatitis exfoliative1913.38 (8.52–20.99)13.36 (216.69)13.33 (8.49)3.74 (2.4)1.7E-153.0E-12Rash morbilliform1822.96 (14.44–36.49)22.94 (375.77)22.83 (14.36)4.51 (2.74)9.8E-191.7E-15Petechiae*165.31 (3.25–8.66)5.3 (55.79)5.3 (3.24)2.41 (1.38)1.3E-072.3E-04Dermatitis allergic164.44 (2.72–7.25)4.44 (42.54)4.43 (2.71)2.15 (1.18)1.4E-062.3E-03Hypersensitivity vasculitis*1616.11 (9.86–26.32)16.1 (225.74)16.04 (9.82)4 (2.39)1.7E-143.0E-11Linear Iga disease*1528.39 (17.09–47.18)28.37 (393.63)28.2 (16.97)4.82 (2.66)3.4E-175.9E-14Dermatitis exfoliative generalized1414.53 (8.59–24.55)14.52 (175.64)14.47 (8.56)3.86 (2.18)2.9E-125.0E-09Fixed eruption*1222.69 (12.87–40.02)22.68 (247.43)22.57 (12.8)4.5 (2.28)6.3E-131.1E-09Exfoliative rash810.24 (5.12–20.49)10.23 (66.51)10.21 (5.1)3.35 (1.37)1.7E-063.0E-03Erythema nodosum*88.11 (4.05–16.23)8.11 (49.77)8.1 (4.05)3.02 (1.22)9.4E-061.6E-02Dermatosis*846.06 (22.95–92.44)46.04 (348.98)45.59 (22.72)5.51 (1.97)1.8E-113.2E-08Subcorneal pustular dermatosis*6179.98 (79.59–406.99)179.92 (1,027.02)173.13 (76.56)7.44 (1.64)2.1E-123.7E-09Prurigo*519.79 (8.22–47.64)19.78 (88.78)19.7 (8.18)4.3 (1.08)7.0E-061.2E-02Oculomucocutaneous syndrome*544.44 (18.41–107.23)44.43 (210.19)44.01 (18.24)5.46 (1.24)1.4E-072.4E-04Sjs-ten overlap429.85 (11.16–79.79)29.84 (110.77)29.65 (11.09)4.89 (0.84)1.2E-052.1E-02Mucocutaneous rash370.5 (22.54–220.52)70.48 (202.37)69.43 (22.19)6.12 (0.48)1.3E-052.2E-02Respiratory, thoracic and mediastinal disordersRespiratory failure1004.72 (3.87–5.74)4.7 (290.92)4.69 (3.85)2.23 (1.89)2.0E-643.5E-61Hypoxia363.63 (2.62–5.04)3.63 (68.46)3.62 (2.61)1.86 (1.28)4.8E-168.4E-13Respiratory distress334.11 (2.92–5.78)4.1 (77.46)4.1 (2.91)2.04 (1.41)6.4E-181.1E-14Eosinophilic pneumonia*3238.2 (26.97–54.11)38.13 (1,147.53)37.82 (26.7)5.24 (3.65)6.8E-391.2E-35Bronchospasm296.92 (4.8–9.96)6.91 (146.36)6.9 (4.79)2.79 (2)2.3E-154.0E-12Acute respiratory failure223.99 (2.63–6.06)3.99 (49.17)3.98 (2.62)1.99 (1.22)1.0E-111.8E-08Acute respiratory distress syndrome193.85 (2.45–6.03)3.84 (39.96)3.84 (2.45)1.94 (1.1)1.2E-062.1E-03Pulmonary hemorrhage*146.08 (3.6–10.28)6.08 (59.34)6.07 (3.59)2.6 (1.44)1.6E-072.8E-04Eosinophilic pneumonia acute*1461.88 (36.51–104.88)61.83 (826.69)61.02 (36)5.93 (2.86)9.5E-211.6E-17Apnoea114.85 (2.68–8.75)4.84 (33.51)4.84 (2.68)2.27 (1.04)2.6E-054.6E-02Respiratory acidosis*87.21 (3.6–14.42)7.2 (42.68)7.2 (3.6)2.85 (1.13)2.2E-053.7E-02Pulmonary eosinophilia*430.04 (11.24–80.31)30.04 (111.54)29.85 (11.16)4.9 (0.84)1.2E-052.1E-02Cheyne-stokes respiration*456.11 (20.93–150.42)56.1 (213.83)55.43 (20.68)5.79 (0.92)1.0E-061.8E-03Respiratory muscle weakness*439.99 (14.94–107.02)39.98 (150.71)39.64 (14.81)5.31 (0.89)3.9E-066.8E-03Renal and urinary disordersAcute kidney injury2173.66 (3.2–4.18)3.62 (413.44)3.62 (3.17)1.86 (1.64)2.4E-914.2E-88Renal impairment1275.27 (4.42–6.27)5.24 (435.5)5.23 (4.39)2.39 (2.08)8.6E-961.5E-92Tubulointerstitial nephritis*599.67 (7.49–12.49)9.64 (456.02)9.62 (7.45)3.27 (2.7)2.6E-994.5E-96Anuria239.03 (6–13.6)9.02 (163.68)9 (5.98)3.17 (2.17)7.6E-151.3E-11Nephropathy toxic*196.14 (3.91–9.62)6.13 (81.48)6.12 (3.9)2.61 (1.64)9.5E-101.6E-06Oliguria116.24 (3.45–11.27)6.23 (48.26)6.23 (3.45)2.64 (1.28)2.6E-064.5E-03Fanconi syndrome acquired*611.12 (4.99–24.78)11.12 (55.11)11.09 (4.98)3.47 (1.09)2.2E-053.8E-02Psychiatric disordersDelirium333.36 (2.39–4.73)3.35 (54.51)3.35 (2.38)1.75 (1.15)5.1E-138.8E-10Pregnancy, puerperium and perinatal conditionsPremature baby*363.97 (2.86–5.5)3.96 (79.68)3.96 (2.85)1.99 (1.4)1.9E-183.4E-15Premature delivery*193.73 (2.38–5.85)3.72 (37.85)3.72 (2.37)1.9 (1.07)3.0E-095.2E-06Low birth weight baby*176.86 (4.26–11.03)6.85 (84.81)6.84 (4.25)2.77 (1.69)1.4E-092.4E-06Nervous system disordersSeizure1713.47 (2.99–4.04)3.45 (298.23)3.45 (2.97)1.79 (1.54)2.7E-664.7E-63Epilepsy11313.11 (10.89–15.77)13.03 (1,252.14)13 (10.8)3.7 (3.28)1.1E-2712.0E-268Encephalopathy*7711.13 (8.89–13.92)11.08 (704.85)11.06 (8.84)3.47 (2.96)4.0E-1536.9E-150Depressed level of consciousness*645.78 (4.52–7.39)5.77 (251.92)5.76 (4.51)2.53 (2.07)1.1E-551.9E-52Neurotoxicity*469.45 (7.07–12.62)9.43 (345.83)9.41 (7.04)3.23 (2.57)7.1E-291.2E-25Generalized tonic-clonic seizure415.62 (4.14–7.64)5.61 (155.33)5.61 (4.13)2.49 (1.89)1.2E-342.1E-31Status epilepticus329.81 (6.93–13.88)9.79 (252.19)9.78 (6.91)3.29 (2.45)4.6E-218.0E-18Myoclonus247.03 (4.71–10.49)7.02 (123.76)7.01 (4.7)2.81 (1.92)4.0E-136.9E-10Toxic encephalopathy*2215.4 (10.13–23.41)15.38 (294.87)15.33 (10.09)3.94 (2.64)6.1E-191.1E-15Altered state of consciousness*223.55 (2.33–5.39)3.54 (40.13)3.54 (2.33)1.82 (1.07)8.5E-101.5E-06Hepatic encephalopathy*165.7 (3.49–9.31)5.7 (61.89)5.69 (3.48)2.51 (1.46)5.2E-089.0E-05Partial seizures128.1 (4.6–14.27)8.09 (74.49)8.08 (4.59)3.01 (1.59)6.1E-081.1E-04Convulsive threshold lowered1197.6 (53.7–177.39)97.55 (1,029.09)95.52 (52.56)6.58 (2.58)9.6E-191.7E-15Tonic clonic movements719.06 (9.07–40.04)19.05 (119.21)18.97 (9.03)4.25 (1.52)1.3E-072.3E-04Febrile convulsion514.78 (6.14–35.57)14.78 (64.03)14.74 (6.12)3.88 (0.98)2.8E-054.9E-02Neoplasms benign, malignant and unspecified (Incl cysts and polyps)Benign neoplasm of bladder*4107.27 (39.8–289.14)107.25 (411.35)104.8 (38.88)6.71 (0.96)8.3E-081.4E-04Musculoskeletal and connective tissue disordersMyopathy*239.32 (6.19–14.03)9.31 (170.21)9.29 (6.17)3.22 (2.2)4.0E-156.9E-12Myositis*145.77 (3.42–9.75)5.77 (55.11)5.76 (3.41)2.53 (1.38)3.0E-075.2E-04Metabolism and nutrition disordersHypokalemia372.82 (2.04–3.89)2.82 (43.34)2.82 (2.04)1.49 (0.96)1.2E-102.0E-07Hyperkalemia*333.25 (2.31–4.57)3.24 (51.19)3.24 (2.3)1.7 (1.11)2.6E-124.5E-09Hyperamylasemia*16102.95 (62.71–169.01)102.86 (1,578.32)100.61 (61.29)6.65 (3.17)5.8E-271.0E-23Hypertriglyceridemia*159.16 (5.52–15.21)9.16 (108.77)9.14 (5.51)3.19 (1.88)2.7E-104.8E-07Hypernatremia*139.26 (5.37–15.95)9.25 (95.47)9.23 (5.36)3.21 (1.77)3.7E-096.4E-06Metabolic alkalosis*1329.05 (16.84–50.13)29.03 (349.64)28.85 (16.72)4.85 (2.5)3.2E-155.6E-12Hyperlipasemia*850.39 (25.1–101.16)50.36 (382.85)49.83 (24.82)5.64 (1.99)9.1E-121.6E-08Vitamin K deficiency*869.62 (34.63–139.97)69.59 (532.69)68.56 (34.1)6.1 (2.04)7.3E-131.3E-09Vitamin C deficiency*598.26 (40.51–238.33)98.23 (471.07)96.18 (39.65)6.59 (1.32)2.9E-095.0E-06Electrolyte depletion*428.19 (10.55–75.33)28.18 (104.22)28.01 (10.48)4.81 (0.83)1.5E-052.7E-02InvestigationsAlanine aminotransferase increased663.88 (3.05–4.94)3.87 (140.58)3.87 (3.04)1.95 (1.54)8.4E-321.5E-28Aspartate aminotransferase increased594.06 (3.15–5.25)4.05 (135.67)4.05 (3.14)2.02 (1.57)1.1E-301.9E-27C-reactive protein increased*575.59 (4.31–7.25)5.57 (213.85)5.57 (4.29)2.48 (1.99)1.9E-473.4E-44Transaminases increased527.93 (6.04–10.41)7.91 (313.4)7.9 (6.01)2.98 (2.41)1.2E-682.2E-65Clostridium test positive*5283.23 (63.24–109.53)82.99 (4,136.88)81.52 (61.94)6.35 (4.62)2.8E-794.8E-76Gamma-glutamyltransferase increased467.35 (5.5–9.82)7.34 (251.49)7.33 (5.49)2.87 (2.27)2.9E-555.0E-52Liver function test abnormal425.06 (3.74–6.85)5.05 (136.44)5.05 (3.73)2.34 (1.77)1.2E-302.1E-27Blood alkaline phosphatase increased395.57 (4.07–7.63)5.56 (145.7)5.55 (4.06)2.47 (1.86)1.5E-322.6E-29White blood cell count increased363.2 (2.31–4.44)3.19 (54.24)3.19 (2.3)1.67 (1.12)5.4E-139.3E-10Anticonvulsant drug level decreased3590.92 (65.04–127.09)90.75 (3,045.9)88.99 (63.67)6.48 (4.21)3.0E-555.2E-52Blood bilirubin increased314 (2.81–5.7)4 (69.7)4 (2.81)2 (1.36)3.1E-165.4E-13International normalized ratio increased*273.23 (2.22–4.72)3.23 (41.54)3.23 (2.21)1.69 (1.03)3.6E-106.2E-07Blood lactate dehydrogenase increased276.01 (4.12–8.77)6.01 (112.55)6 (4.11)2.58 (1.8)5.1E-138.9E-10Blood creatine phosphokinase increased*253.05 (2.06–4.51)3.04 (34.32)3.04 (2.06)1.61 (0.93)1.3E-082.3E-05Body temperature increased*244.1 (2.74–6.12)4.09 (56.06)4.09 (2.74)2.03 (1.29)3.3E-135.8E-10Eosinophil count increased2310.01 (6.65–15.07)10 (185.88)9.98 (6.63)3.32 (2.27)9.1E-161.6E-12Anticonvulsant drug level below therapeutic22113.96 (74.63–174.01)113.82 (2,400.34)111.07 (72.74)6.8 (3.65)1.9E-373.3E-34Prothrombin time prolonged1710.36 (6.43–16.67)10.35 (143.22)10.33 (6.41)3.37 (2.08)2.8E-124.9E-09Procalcitonin increased*1545.8 (27.54–76.18)45.76 (650.26)45.32 (27.25)5.5 (2.86)3.3E-205.7E-17Activated partial thromboplastin time prolonged1510.96 (6.6–18.19)10.95 (135.3)10.93 (6.58)3.45 (2.03)2.4E-114.2E-08Amylase increased*138.72 (5.06–15.02)8.71 (88.58)8.7 (5.05)3.12 (1.72)7.4E-091.3E-05Inflammatory marker increased*96.4 (3.33–12.3)6.39 (40.89)6.39 (3.32)2.67 (1.14)1.7E-053.0E-02Staphylococcus test positive*811.45 (5.72–22.93)11.45 (76.1)11.42 (5.71)3.51 (1.44)7.7E-071.3E-03Prothrombin level decreased*727.35 (13.01–57.51)27.34 (176.58)27.18 (12.93)4.76 (1.65)1.2E-082.0E-05Enterococcus test positive*736.23 (17.22–76.23)36.22 (237.82)35.94 (17.08)5.17 (1.72)1.7E-093.0E-06Apgar score low*616.95 (7.6–37.79)16.94 (89.69)16.89 (7.57)4.08 (1.28)2.0E-063.5E-03Blood fibrinogen decreased*620.03 (8.98–44.66)20.02 (107.95)19.94 (8.94)4.32 (1.33)7.9E-071.4E-03Human herpes virus 6 serology positive*474.13 (27.6–199.11)74.11 (283.89)72.94 (27.16)6.19 (0.94)3.5E-076.1E-04Aspergillus test positive*444.81 (16.73–119.97)44.8 (169.61)44.37 (16.57)5.47 (0.9)2.5E-064.4E-03Blood beta-D-glucan increased*449.42 (18.45–132.39)49.41 (187.68)48.89 (18.25)5.61 (0.91)1.7E-063.0E-03Anti factor V antibody*3506.53 (153.65–1,669.85)506.45 (1,362.01)455.9 (138.29)8.83 (0.46)4.3E-087.4E-05Minimum inhibitory concentration increased*3569.85 (171.58–1,892.6)569.75 (1,514.01)506.56 (152.52)8.98 (0.45)3.1E-085.3E-05Injury, poisoning and procedural complicationsContraindicated product administered*293.19 (2.21–4.59)3.18 (43.41)3.18 (2.21)1.67 (1.04)1.3E-102.3E-07Documented hypersensitivity to administered product*720.28 (9.65–42.61)20.27 (127.67)20.19 (9.61)4.34 (1.55)8.7E-081.5E-04Contraindicated product prescribed*610.71 (4.8–23.86)10.7 (52.66)10.68 (4.79)3.42 (1.07)2.7E-054.7E-02Radiation fibrosis—lung*4230.84 (84.53–630.38)230.79 (871.06)219.71 (80.46)7.78 (0.97)4.2E-097.3E-06Infections and infestationsSeptic shock*17514.22 (12.25–16.5)14.09 (2,123.17)14.05 (12.1)3.81 (3.49)0.0E+000.0E+00Sepsis1394.25 (3.6–5.02)4.23 (342.63)4.22 (3.57)2.08 (1.8)8.6E-761.5E-72Clostridium difficile infection7010.51 (8.31–13.3)10.48 (598.97)10.46 (8.27)3.39 (2.86)3.1E-1305.4E-127Clostridium difficile colitis6621.35 (16.76–27.21)21.28 (1,269.74)21.18 (16.63)4.4 (3.67)2.5E-624.3E-59Candida infection6210.46 (8.15–13.42)10.42 (527.21)10.4 (8.1)3.38 (2.81)1.2E-1142.2E-111Pseudomembranous colitis4570.93 (52.82–95.24)70.75 (3,047.29)69.69 (51.89)6.12 (4.38)8.6E-661.5E-62Systemic candida4262.38 (45.99–84.61)62.24 (2,496.58)61.41 (45.27)5.94 (4.23)3.1E-595.4E-56Fungal infection404 (2.93–5.45)3.99 (89.69)3.99 (2.93)2 (1.44)1.2E-202.2E-17Staphylococcal infection*313.23 (2.27–4.59)3.22 (47.51)3.22 (2.26)1.69 (1.08)1.7E-112.9E-08Klebsiella infection*2618.66 (12.69–27.44)18.64 (432.28)18.57 (12.63)4.21 (2.93)3.8E-246.7E-21Fungemia2557.22 (38.56–84.92)57.15 (1,362.06)56.45 (38.04)5.82 (3.6)5.1E-358.9E-32Bacteremia257.51 (5.07–11.12)7.5 (140.72)7.49 (5.06)2.91 (2.02)3.1E-145.4E-11Bronchopulmonary aspergillosis*2511.4 (7.7–16.88)11.38 (236.23)11.36 (7.67)3.51 (2.45)2.8E-184.8E-15Pseudomonas infection*239.85 (6.54–14.83)9.84 (182.2)9.82 (6.52)3.3 (2.25)1.3E-152.2E-12Enterococcal infection*1914.23 (9.07–22.33)14.21 (232.68)14.17 (9.03)3.83 (2.45)5.9E-161.0E-12Endocarditis*1711.52 (7.16–18.55)11.51 (162.78)11.49 (7.13)3.52 (2.18)5.3E-139.3E-10Liver abscess*1617.11 (10.47–27.96)17.1 (241.57)17.04 (10.42)4.09 (2.43)7.0E-151.2E-11Fungal sepsis*1564.49 (38.73–107.38)64.44 (923.78)63.56 (38.17)5.99 (2.97)2.2E-223.8E-19Stenotrophomonas infection*1540.27 (24.22–66.97)40.24 (568.98)39.9 (23.99)5.32 (2.81)2.1E-193.7E-16Acinetobacter infection*1446.24 (27.31–78.3)46.21 (613)45.75 (27.02)5.52 (2.77)5.1E-198.8E-16Pneumonia bacterial*135.28 (3.07–9.11)5.28 (45.07)5.28 (3.06)2.4 (1.24)2.0E-063.5E-03Enterobacter infection*1328.24 (16.36–48.72)28.22 (339.18)28.05 (16.26)4.81 (2.48)4.6E-157.9E-12Neutropenic sepsis*136.14 (3.56–10.57)6.13 (55.76)6.12 (3.55)2.61 (1.39)4.0E-076.9E-04Superinfection1229.13 (16.51–51.39)29.11 (323.66)28.93 (16.4)4.85 (2.4)3.6E-146.2E-11Candida sepsis*1247.88 (27.11–84.58)47.85 (544.78)47.37 (26.81)5.57 (2.57)1.1E-161.9E-13Infectious pleural effusion*1225.87 (14.66–45.63)25.85 (285.04)25.71 (14.57)4.68 (2.34)1.4E-132.4E-10Encephalitis*115.58 (3.09–10.08)5.58 (41.27)5.57 (3.08)2.48 (1.18)7.3E-061.3E-02Trichosporon infection*1089.77 (48–167.89)89.72 (860.43)88.01 (47.06)6.46 (2.42)8.2E-171.4E-13Staphylococcal bacteremia*108.51 (4.57–15.82)8.5 (66.08)8.49 (4.56)3.09 (1.47)4.8E-078.4E-04Escherichia urinary tract infection*107.93 (4.26–14.74)7.92 (60.39)7.91 (4.25)2.98 (1.41)9.1E-071.6E-03Clostridial infection*911.06 (5.75–21.28)11.06 (82.13)11.03 (5.74)3.46 (1.55)2.1E-073.6E-04Brain abscess*811.12 (5.56–22.27)11.12 (73.51)11.1 (5.54)3.47 (1.42)9.5E-071.6E-03Meningitis candida*8384 (186.6–790.25)383.83 (2,817.43)354.1 (172.07)8.47 (2.13)1.2E-182.2E-15Meningitis bacterial*818.98 (9.48–38.01)18.97 (135.64)18.9 (9.44)4.24 (1.7)1.7E-083.0E-05Lung abscess*711.67 (5.56–24.51)11.67 (68.09)11.64 (5.54)3.54 (1.3)3.3E-065.8E-03Klebsiella bacteremia*728.32 (13.47–59.55)28.31 (183.29)28.14 (13.38)4.81 (1.66)9.2E-091.6E-05Nosocomial infection*710.49 (4.99–22.02)10.48 (59.9)10.46 (4.98)3.39 (1.24)6.6E-061.1E-02Pneumonia necrotising*739.95 (18.98–84.08)39.93 (263.4)39.59 (18.81)5.31 (1.74)8.9E-101.6E-06Gastroenteritis staphylococcal*7154.19 (72.59–327.53)154.14 (1,030.16)149.13 (70.21)7.22 (1.89)8.7E-141.5E-10Urinary tract infection fungal*742.05 (19.98–88.53)42.04 (277.87)41.66 (19.79)5.38 (1.75)6.3E-101.1E-06Sepsis neonatal*626.56 (11.9–59.27)26.55 (146.68)26.4 (11.83)4.72 (1.42)1.6E-072.7E-04Enterococcal sepsis*625.52 (11.44–56.94)25.51 (140.52)25.37 (11.37)4.67 (1.41)2.0E-073.4E-04Clostridial sepsis*659.09 (26.4–132.22)59.07 (338.12)58.32 (26.06)5.87 (1.57)1.5E-092.5E-06Hematological infection*613.52 (6.06–30.13)13.51 (69.31)13.47 (6.05)3.75 (1.18)7.4E-061.3E-02Septic embolus*520.97 (8.71–50.49)20.97 (94.63)20.87 (8.67)4.38 (1.09)5.3E-069.3E-03Intracranial infection*5186.86 (76.39–457.04)186.8 (887.67)179.49 (73.38)7.49 (1.34)1.3E-102.2E-07Corynebacterium infection*535.18 (14.59–84.82)35.17 (164.72)34.91 (14.48)5.13 (1.21)4.4E-077.6E-04Rhinocerebral mucormycosis*565.13 (26.94–157.48)65.11 (311.2)64.21 (26.56)6 (1.29)2.2E-083.8E-05Pyometra*4189.96 (69.86–516.52)189.92 (721.62)182.36 (67.07)7.51 (0.97)8.9E-091.5E-05Typhoid fever*444.05 (16.45–117.93)44.04 (166.64)43.63 (16.29)5.45 (0.9)2.7E-064.7E-03Superinfection fungal4214.54 (78.7–584.88)214.49 (811.8)204.9 (75.16)7.68 (0.97)5.6E-099.7E-06Rotavirus infection*425.22 (9.44–67.39)25.22 (92.52)25.08 (9.39)4.65 (0.81)2.4E-054.1E-02Pneumonia moraxella*4172.04 (63.39–466.91)172 (655.3)165.78 (61.08)7.37 (0.97)1.3E-082.3E-05Abscess bacterial*437.22 (13.91–99.57)37.21 (139.8)36.92 (13.8)5.21 (0.88)5.2E-069.0E-03Cns ventriculitis*443.11 (16.1–115.41)43.1 (162.96)42.71 (15.95)5.42 (0.89)2.9E-065.1E-03Candida endophthalmitis*4116.15 (43.05–313.38)116.13 (445.2)113.27 (41.98)6.82 (0.96)6.1E-081.1E-04Osteomyelitis bacterial*451.95 (19.39–139.22)51.94 (197.6)51.37 (19.17)5.68 (0.91)1.4E-062.5E-03Renal cyst infection*479.98 (29.76–214.97)79.97 (306.53)78.6 (29.25)6.3 (0.95)2.6E-074.5E-04Herpes simplex oesophagitis*475.67 (28.17–203.28)75.65 (289.85)74.43 (27.71)6.22 (0.94)3.2E-075.6E-04Urinary tract candidiasis*444.92 (16.77–120.27)44.91 (170.04)44.48 (16.61)5.48 (0.9)2.5E-064.3E-03Penicillium infection*359.2 (18.95–184.94)59.19 (169.44)58.45 (18.71)5.87 (0.47)2.1E-053.7E-02Cutaneous mucormycosis*379.98 (25.54–250.47)79.97 (229.9)78.6 (25.1)6.3 (0.49)8.9E-061.5E-02Endocarditis candida*3140.99 (44.69–444.87)140.97 (404.42)136.77 (43.35)7.1 (0.5)1.7E-062.9E-03Immune system disordersAnaphylactic reaction855.51 (4.45–6.82)5.49 (311.7)5.48 (4.43)2.45 (2.07)8.8E-691.5E-65Anaphylactic shock598.27 (6.41–10.69)8.25 (375.41)8.24 (6.38)3.04 (2.5)4.6E-828.0E-79Type IV hypersensitivity reaction*2734.23 (23.43–49.99)34.18 (863.1)33.93 (23.23)5.08 (3.41)8.0E-321.4E-28Haemophagocytic lymphohistiocytosis*155.38 (3.24–8.93)5.38 (53.4)5.37 (3.24)2.43 (1.35)2.7E-074.8E-04Cross sensitivity reaction1421.87 (12.93–36.98)21.85 (277.27)21.75 (12.86)4.44 (2.44)1.3E-142.2E-11Jarisch–Herxheimer reaction*1356.36 (32.61–97.42)56.33 (697.84)55.65 (32.2)5.8 (2.73)7.4E-191.3E-15Serum sickness-like reaction*846.53 (23.18–93.39)46.51 (352.66)46.05 (22.94)5.53 (1.97)1.7E-113.0E-08Hepatobiliary disordersHepatic function abnormal*12111.87 (9.92–14.2)11.8 (1,193.31)11.77 (9.84)3.56 (3.17)3.8E-2596.5E-256Drug-induced liver injury*697.87 (6.22–9.98)7.85 (411.84)7.84 (6.19)2.97 (2.49)4.4E-907.7E-87Cholestasis6512 (9.4–15.31)11.96 (651.13)11.93 (9.35)3.58 (3)3.0E-1415.1E-138Hepatitis*527.26 (5.53–9.54)7.25 (279.68)7.24 (5.51)2.86 (2.3)2.0E-613.4E-58Liver disorder*463.67 (2.74–4.9)3.66 (88.9)3.66 (2.74)1.87 (1.37)1.6E-202.7E-17Liver injury*386.06 (4.41–8.33)6.05 (160)6.04 (4.39)2.6 (1.96)1.4E-352.4E-32Hepatic cytolysis*3812.08 (8.78–16.61)12.05 (384.19)12.02 (8.74)3.59 (2.77)8.0E-281.4E-24Hyperbilirubinemia3411.4 (8.14–15.97)11.38 (321.24)11.36 (8.11)3.51 (2.64)2.7E-244.7E-21Hepatocellular injury*295.46 (3.8–7.87)5.46 (105.47)5.45 (3.79)2.45 (1.72)8.9E-241.5E-20Hepatotoxicity*264.11 (2.8–6.04)4.11 (61.1)4.11 (2.79)2.04 (1.32)2.6E-144.5E-11Hypertransaminasemia2011.72 (7.56–18.18)11.71 (195.39)11.68 (7.53)3.55 (2.32)3.7E-156.4E-12Vanishing bile duct syndrome*1963.74 (40.52–100.27)63.68 (1,156.05)62.81 (39.93)5.97 (3.29)7.4E-281.3E-24Hepatitis cholestatic1810.94 (6.89–17.38)10.93 (162.07)10.91 (6.87)3.45 (2.18)2.6E-134.6E-10Acute hepatic failure174.34 (2.7–6.99)4.34 (43.64)4.34 (2.69)2.12 (1.19)8.6E-071.5E-03Hepatitis acute158.08 (4.87–13.41)8.08 (92.84)8.06 (4.86)3.01 (1.76)1.5E-092.5E-06Jaundice cholestatic1312.88 (7.47–22.2)12.87 (141.93)12.84 (7.45)3.68 (2.03)7.3E-111.3E-07Mixed liver injury*1013.53 (7.27–25.18)13.53 (115.65)13.49 (7.25)3.75 (1.79)7.0E-091.2E-05Hepatitis toxic*912.17 (6.33–23.42)12.17 (92.02)12.14 (6.31)3.6 (1.61)9.5E-081.6E-04Hepatitis fulminant*910.97 (5.7–21.11)10.97 (81.34)10.94 (5.69)3.45 (1.54)2.2E-073.9E-04Cholestatic liver injury*814.18 (7.08–28.38)14.17 (97.64)14.13 (7.06)3.82 (1.56)1.6E-072.7E-04Hepatic infarction*544.96 (18.63–108.51)44.95 (212.77)44.52 (18.45)5.48 (1.25)1.3E-072.3E-04General disorders and administration site conditionsPyrexia2902.92 (2.6–3.28)2.89 (360.35)2.89 (2.57)1.53 (1.35)6.1E-801.1E-76Multiple organ dysfunction syndrome*15612.32 (10.52–14.42)12.22 (1,603.61)12.19 (10.41)3.61 (3.28)0.0E+000.0E+00Treatment failure853.58 (2.9–4.44)3.57 (157.56)3.57 (2.89)1.84 (1.48)1.4E-352.4E-32Face edema306.22 (4.35–8.9)6.21 (131.02)6.2 (4.34)2.63 (1.89)1.2E-142.0E-11Hyperpyrexia1513.24 (7.97–21.98)13.23 (169.1)13.19 (7.95)3.72 (2.18)1.8E-123.1E-09Catheter site pain*1215.87 (9–27.97)15.86 (166.49)15.81 (8.97)3.98 (2.08)3.7E-116.5E-08Systemic inflammatory response syndrome119.39 (5.2–16.97)9.39 (82.25)9.37 (5.18)3.23 (1.63)5.0E-088.6E-05Extravasation*108.14 (4.38–15.14)8.14 (62.49)8.12 (4.37)3.02 (1.43)7.2E-071.2E-03Catheter site swelling*621.51 (9.64–47.97)21.5 (116.73)21.4 (9.6)4.42 (1.36)5.2E-079.1E-04Polyserositis*435.07 (13.11–93.8)35.06 (131.35)34.8 (13.01)5.12 (0.87)6.6E-061.1E-02Catheter site warmth*485.22 (31.69–229.16)85.2 (326.73)83.65 (31.11)6.39 (0.95)2.0E-073.5E-04Gastrointestinal disordersDysbiosis*33124.02 (87.74–175.31)123.8 (3,913.37)120.55 (85.28)6.91 (4.24)1.5E-562.6E-53Megacolon*1022 (11.82–40.95)21.99 (199.37)21.89 (11.76)4.45 (2.04)7.1E-111.2E-07Pancreatitis necrotising*913.39 (6.96–25.77)13.39 (102.87)13.35 (6.94)3.74 (1.66)4.3E-087.4E-05Infantile diarrhea8160 (79.04–323.87)159.93 (1,220.67)154.54 (76.35)7.27 (2.12)1.1E-151.9E-12Neutropenic colitis*610.65 (4.78–23.74)10.65 (52.34)10.63 (4.77)3.41 (1.07)2.8E-054.8E-02Abdominal compartment syndrome*633.4 (14.96–74.58)33.39 (187.16)33.16 (14.85)5.05 (1.47)4.1E-087.1E-05Ear and labyrinth disordersOtotoxicity*610.99 (4.93–24.48)10.98 (54.32)10.96 (4.92)3.45 (1.08)2.3E-054.0E-02Cardiac disordersCardiac arrest682.88 (2.27–3.65)2.87 (82.83)2.87 (2.26)1.52 (1.13)2.3E-194.0E-16Eosinophilic myocarditis*629.26 (13.11–65.3)29.25 (162.66)29.07 (13.02)4.86 (1.44)8.9E-081.5E-04Cardiovascular insufficiency*612.22 (5.48–27.24)12.22 (61.65)12.19 (5.47)3.61 (1.14)1.3E-052.2E-02Blood and lymphatic system disordersPancytopenia*18111.56 (9.98–13.38)11.45 (1,723.99)11.43 (9.87)3.51 (3.22)0.0E+000.0E+00Thrombocytopenia1765.58 (4.81–6.48)5.54 (655.06)5.53 (4.77)2.47 (2.21)1.7E-1433.0E-140Eosinophilia13327.32 (23.02–32.42)27.12 (3,327.63)26.97 (22.73)4.75 (4.25)3.3E-1375.7E-134Leukopenia735.1 (4.05–6.41)5.08 (239.1)5.07 (4.03)2.34 (1.93)4.8E-538.3E-50Bone marrow failure*669.74 (7.64–12.4)9.7 (514.31)9.68 (7.6)3.28 (2.75)5.6E-1129.7E-109Agranulocytosis5911.48 (8.89–14.83)11.44 (561.1)11.42 (8.84)3.51 (2.91)8.7E-1221.5E-118Disseminated intravascular coagulation*5012.5 (9.47–16.51)12.47 (526.22)12.44 (9.42)3.64 (2.94)9.2E-371.6E-33Myelosuppression*314.26 (2.99–6.06)4.25 (77.05)4.25 (2.99)2.09 (1.44)8.5E-181.5E-14Coagulopathy*275.58 (3.83–8.14)5.57 (101.24)5.57 (3.82)2.48 (1.71)2.8E-124.8E-09Lymphopenia*194.67 (2.98–7.33)4.67 (54.76)4.67 (2.98)2.22 (1.33)6.7E-081.2E-04Leukocytosis193.72 (2.37–5.84)3.72 (37.73)3.72 (2.37)1.89 (1.06)3.2E-095.5E-06Thrombocytosis1815.4 (9.7–24.47)15.39 (241.39)15.34 (9.66)3.94 (2.46)8.8E-161.5E-12Methaemoglobinemia*1828.11 (17.68–44.68)28.08 (467.19)27.91 (17.56)4.8 (2.87)3.0E-205.2E-17Thrombocytopenia neonatal17153.58 (94.7–249.08)153.44 (2,490.73)148.47 (91.55)7.21 (3.32)1.9E-313.3E-28Hypocoagulable state*1033.56 (18.01–62.52)33.54 (313.39)33.3 (17.87)5.06 (2.21)1.2E-122.1E-09Hypereosinophilic syndrome*961.72 (31.97–119.16)61.69 (530.16)60.88 (31.53)5.93 (2.2)7.7E-141.3E-10Haemorrhagic disorder*824.77 (12.36–49.62)24.75 (181.38)24.63 (12.29)4.62 (1.8)2.3E-093.9E-06Monocytopenia*6205.69 (90.76–466.16)205.62 (1,169.04)196.79 (86.83)7.62 (1.65)9.7E-131.7E-09Bicytopenia*611.44 (5.13–25.5)11.44 (57.01)11.41 (5.12)3.51 (1.11)1.9E-053.2E-02Factor V inhibition*575.48 (31.19–182.69)75.46 (361.4)74.25 (30.68)6.21 (1.3)1.1E-081.8E-05Neutropenia neonatal469.08 (25.73–185.44)69.06 (264.3)68.04 (25.35)6.09 (0.94)4.6E-078.1E-04Cyclic neutropenia4268.18 (97.82–735.22)268.12 (1,005.35)253.28 (92.39)7.98 (0.96)2.4E-094.1E-06Splenic embolism*393.04 (29.66–291.83)93.02 (267.63)91.18 (29.07)6.51 (0.49)5.7E-069.8E-03*Indicates adverse event PTs that are not explicitly labeled in the FDA prescribing information. Overall positive adverse event signals associated with meropenem identified using four pharmacovigilance algorithms and Bonferroni correction. *Indicates adverse event PTs that are not explicitly labeled in the FDA prescribing information. Age-stratified distribution of meropenem-related adverse event signals. (A) SOC-level heat map showing the age-graded distribution of SOC-level counties derived from robust pt-level signals. Colors indicate row-wise Z scores calculated from SOC-specific signal counts. (B) PT-level heatmap showing representative robust PT signals across age groups. Colors indicate row-wise Z scores calculated from PT-specific signal counts, with positive values indicating relatively enriched reporting within a given age group. PT, preferred term; SOC, system organ class. Ranked by report frequency, the most commonly reported PT signals included pyrexia, acute kidney injury, pancytopenia, thrombocytopenia, septic shock, seizure, drug reaction with eosinophilia and systemic symptoms (DRESS), multiple organ dysfunction syndrome, sepsis, and eosinophilia (Table 2). The overall signal distribution indicated that frequently reported signals involved infection progression, renal injury, and hematologic abnormalities, severe cutaneous adverse reactions, and immune-mediated events (Supplementary Figure 2B). Several PTs with relatively low report frequency but disproportionately strong signal strength also warranted attention. For example, DRESS, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis exhibited particularly strong disproportionality signals. These findings suggest that, in addition to common infection- and renal-related events, clinical monitoring should also pay attention to severe cutaneous reactions and immune hypersensitivity reactions (Table 2). Time-to-onset and Weibull parameter analysis A total of 1,371 reports with complete treatment initiation and event onset dates were included in the TTO analysis. The median TTO was 5 days (IQR: 2–12 days), suggesting an early accumulation of reported events among date-complete reports (Table 3). The cumulative incidence curve demonstrated rapid accumulation of AEs shortly after treatment initiation, followed by a gradual plateau phase (Figure 4A). Following sex stratification, the median TTO was 6 days in females and 5 days in males, with broadly similar overall distributions (Figure 4B). Furthermore, PT signal distributions showed some variation between male and female reports (Supplementary Figure 1). Certain PTs exhibited relatively stronger disproportionality signals in either males or females; however, most PTs clustered within regions of limited difference, suggesting that the overall meropenem-associated AE spectrum was largely comparable between sexes, with only a minority of events potentially exhibiting sex-related differences (Figure 4C and Supplementary Figure 1). Weibull parameter analysis showed a scale parameter (α) of 10.49 (95% CI: 9.67–11.30) and a shape parameter (β) of 0.72 (95% CI: 0.70–0.75), indicating an early-reporting pattern among reports included in the TTO subset (Table 3). To further examine event-category-specific temporal patterns, exploratory SOC-level TTO analyses were performed using report–SOC pairs. The SOC-level results showed that several major SOCs had relatively early median TTO values, although temporal distributions and Weibull parameters varied across categories. These findings indicate that the overall Weibull estimate should be interpreted as a summary of the temporal reporting pattern rather than a uniform onset profile across all SOC categories. Detailed SOC-level TTO distributions and Weibull parameters are provided in Supplementary Table 4. Stratification by onset interval further supported the finding that meropenem-associated AEs were predominantly concentrated in the early accumulation of reported events during the initial treatment period (Figure 4D). Table 3Time-to-onset characteristics and Weibull parameter analysis of meropenem-related adverse events.CasesTTOWeibull distributionFailure typeMedian (IQR)Scale parameterShape parameterα (95% CI)β (95% CI)1,3715 (2–12)10.49 (9.67–11.30)0.72 (0.70–0.75)Early-reporting patternTTO, time to onset; IQR, interquartile range; CI, confidence interval.α represents the scale parameter of the Weibull distribution, and β represents the shape parameter. A shape parameter (β) < 1 indicates an early failure pattern, β = 1 indicates a random failure pattern, and β > 1 indicates a late failure pattern. Time-to-onset characteristics and Weibull parameter analysis of meropenem-related adverse events. TTO, time to onset; IQR, interquartile range; CI, confidence interval. α represents the scale parameter of the Weibull distribution, and β represents the shape parameter. A shape parameter (β) < 1 indicates an early failure pattern, β = 1 indicates a random failure pattern, and β > 1 indicates a late failure pattern. Overall characteristics of meropenem-related adverse events. (A) Cumulative distribution of time-to-onset among all meropenem-related adverse event reports. (B) Sex-stratified cumulative distribution of time-to-onset. (C) Volcano plot showing the distribution of adverse event signals according to signal strength and statistical significance. (D) Distribution of time-to-onset intervals for meropenem-related adverse events. Age-stratified PT signal characteristics Overall, age-related heterogeneity was observed at both the PT and SOC levels. A total of 458 PT signals were identified in the complete age-stratified analysis (Supplementary Table 2), with the highest number observed in the 60–79-year group, followed by the 40–59, 18–39, ≥80, and < 18-year groups (Supplementary Figure 2A). In the < 18-year group, major signals included DRESS, bone marrow failure, hepatic function abnormal, anaphylactic reaction, and sepsis (Table 4). Relatively age-specific signals, including neutropenia neonatal, infantile diarrhea, impaired gastric emptying, and tooth discoloration, were also identified in this group (Supplementary Table 2), suggesting that hematologic, hepatobiliary, gastrointestinal, and pediatric-specific adverse events warrant particular attention among pediatric and adolescent patients. Table 4Age-stratified robust adverse event signals associated with meropenem in the FAERS database.Age_groupPTSOCCaseROR (95%CI)PRR (χ2)EBGM (EBGM05)IC (IC025)P-valueBonferroni P-value<18Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders2510.90 (7.34–16.20)10.78 (220.52)10.71 (7.21)3.42 (2.39)9.011E-184.48748E-15<18Bone marrow failureBlood and lymphatic system disorders2416.96 (11.32–25.42)16.77 (352.35)16.60 (11.08)4.05 (2.77)2.22061E-211.10587E-18<18Hepatic function abnormalHepatobiliary disorders2116.54 (10.74–25.49)16.38 (300.27)16.22 (10.53)4.02 (2.64)1.0754E-185.3555E-16<18Anaphylactic reactionImmune system disorders206.24 (4.01–9.70)6.18 (86.69)6.16 (3.96)2.62 (1.67)2.8939E-101.44116E-07<18SepsisInfections and infestations185.06 (3.18–8.06)5.03 (57.96)5.01 (3.15)2.33 (1.38)4.87921E-082.42985E-05<18ThrombocytopeniaBlood and lymphatic system disorders174.34 (2.69–6.99)4.31 (43.13)4.30 (2.66)2.10 (1.18)9.2602E-070.000461158<18Multiple organ dysfunction syndromeGeneral disorders and administration site conditions176.04 (3.75–9.75)6.00 (70.67)5.98 (3.71)2.58 (1.54)9.34153E-094.65208E-06<18Septic shockInfections and infestations168.50 (5.19–13.92)8.44 (104.43)8.40 (5.13)3.07 (1.84)2.2309E-101.11099E-07<18Candida infectionInfections and infestations1520.66 (12.39–34.44)20.50 (274.85)20.26 (12.15)4.34 (2.47)3.70858E-151.84687E-12<18PancytopeniaBlood and lymphatic system disorders146.31 (3.73–10.69)6.27 (61.88)6.25 (3.69)2.64 (1.46)1.08608E-075.4087E-05<18HypertriglyceridemiaMetabolism and nutrition disorders1320.61 (11.90–35.68)20.48 (237.83)20.23 (11.68)4.34 (2.31)2.54117E-131.2655E-10<18EpilepsyNervous system disorders124.54 (2.57–8.01)4.51 (32.78)4.50 (2.55)2.17 (1.02)2.25964E-050.01125299<18Transaminases increasedInvestigations117.71 (4.26–13.97)7.67 (63.59)7.64 (4.22)2.93 (1.46)3.56026E-070.000177301<18Rash maculo-papularSkin and subcutaneous tissue disorders107.46 (4.00–13.91)7.43 (55.41)7.40 (3.97)2.89 (1.35)1.59895E-060.000796275<18Thrombocytopenia neonatalBlood and lymphatic system disorders973.77 (37.76–144.14)73.44 (614.59)70.23 (35.94)6.13 (2.21)1.88882E-149.40631E-1218–39PyrexiaGeneral disorders and administration site conditions563.87 (2.97–5.05)3.80 (116.26)3.80 (2.91)1.93 (1.47)1.71042E-268.51788E-2418–39Acute kidney injuryRenal and urinary disorders255.80 (3.91–8.60)5.74 (97.94)5.73 (3.87)2.52 (1.71)8.61639E-124.29096E-0918–39Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders2212.67 (8.32–19.30)12.56 (233.46)12.52 (8.22)3.65 (2.45)3.58881E-171.78723E-1418–39NeutropeniaBlood and lymphatic system disorders214.55 (2.96–6.99)4.52 (57.55)4.51 (2.94)2.17 (1.34)2.33658E-081.16362E-0518–39Septic shockInfections and infestations2117.41 (11.32–26.78)17.25 (320.25)17.18 (11.17)4.10 (2.69)3.65995E-191.82266E-1618–39EosinophiliaBlood and lymphatic system disorders2027.20 (17.48–42.30)26.96 (496.69)26.78 (17.22)4.74 (2.95)5.10679E-222.54318E-1918–39Rash maculo-papularSkin and subcutaneous tissue disorders1919.71 (12.53–30.99)19.55 (332.89)19.46 (12.37)4.28 (2.69)1.85626E-189.24416E-1618–39PancytopeniaBlood and lymphatic system disorders1812.55 (7.89–19.98)12.46 (189.24)12.42 (7.81)3.63 (2.29)2.89678E-141.4426E-1118–39Hepatic function abnormalHepatobiliary disorders1713.30 (8.25–21.45)13.21 (191.27)13.17 (8.16)3.72 (2.29)5.95268E-142.96444E-1118–39Multiple organ dysfunction syndromeGeneral disorders and administration site conditions169.87 (6.03–16.15)9.80 (126.26)9.78 (5.98)3.29 (1.99)2.54999E-111.2699E-0818–39SepsisInfections and infestations155.54 (3.34–9.22)5.51 (55.42)5.51 (3.31)2.46 (1.38)1.95363E-079.72905E-0518–39ThrombocytopeniaBlood and lymphatic system disorders144.98 (2.94–8.42)4.95 (44.15)4.95 (2.92)2.31 (1.22)1.70602E-060.00084959818–39Transaminases increasedInvestigations1413.00 (7.68–22.01)12.92 (153.60)12.89 (7.61)3.69 (2.10)1.26288E-116.28914E-0918–39Generalized tonic-clonic seizureNervous system disorders146.53 (3.86–11.06)6.50 (65.09)6.49 (3.84)2.70 (1.50)7.04616E-083.50899E-0518–39Anaphylactic reactionImmune system disorders134.87 (2.82–8.40)4.84 (39.66)4.84 (2.80)2.27 (1.15)4.9787E-060.00247939540–59RashSkin and subcutaneous tissue disorders832.61 (2.10–3.24)2.58 (80.80)2.58 (2.07)1.37 (1.02)5.55417E-194.22117E-1640–59Acute kidney injuryRenal and urinary disorders624.34 (3.38–5.58)4.29 (156.91)4.29 (3.34)2.10 (1.66)2.79267E-352.12243E-3240–59Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders5824.10 (18.59–31.25)23.80 (1,260.21)23.67 (18.25)4.56 (3.72)8.82163E-586.70444E-5540–59ThrombocytopeniaBlood and lymphatic system disorders486.38 (4.80–8.48)6.32 (215.18)6.32 (4.75)2.66 (2.10)1.45415E-471.10515E-4440–59Multiple organ dysfunction syndromeGeneral disorders and administration site conditions4313.52 (10.01–18.26)13.40 (492.04)13.36 (9.89)3.74 (2.94)3.8571E-332.9314E-3040–59SepsisInfections and infestations435.63 (4.17–7.60)5.58 (161.85)5.58 (4.13)2.48 (1.90)4.41256E-363.35355E-3340–59EosinophiliaBlood and lymphatic system disorders4131.51 (23.14-42.90)31.23 (1,190.94)31.00 (22.77)4.95 (3.73)5.71484E-464.34328E-4340–59Septic shockInfections and infestations3811.85 (8.61–16.32)11.76 (373.26)11.73 (8.52)3.55 (2.74)1.72304E-271.30951E-2440–59PancytopeniaBlood and lymphatic system disorders379.58 (6.93–13.25)9.51 (281.38)9.49 (6.86)3.25 (2.48)1.02584E-237.7964E-2140–59SeizureNervous system disorders353.32 (2.38–4.64)3.31 (56.39)3.30 (2.37)1.72 (1.15)1.90532E-131.44804E-1040–59Rash maculo-papularSkin and subcutaneous tissue disorders3319.25 (13.65–27.13)19.11 (563.95)19.03 (13.50)4.25 (3.14)1.40534E-301.06806E-2740–59Renal impairmentRenal and urinary disorders316.30 (4.42–8.97)6.26 (137.08)6.26 (4.39)2.65 (1.91)3.26077E-152.47818E-1240–59CholestasisHepatobiliary disorders2717.86 (12.22–26.09)17.76 (425.27)17.68 (12.10)4.14 (2.92)1.71209E-241.30119E-2140–59LeukopeniaBlood and lymphatic system disorders266.28 (4.27–9.23)6.25 (114.50)6.24 (4.24)2.64 (1.83)5.57115E-134.23408E-1040–59Hepatic function abnormalHepatobiliary disorders269.29 (6.31–13.66)9.24 (190.72)9.22 (6.27)3.20 (2.26)7.72997E-175.87478E-1460–79RashSkin and subcutaneous tissue disorders1042.57 (2.12–3.12)2.54 (97.96)2.54 (2.09)1.35 (1.04)9.34432E-238.28841E-2060–79Acute kidney injuryRenal and urinary disorders913.17 (2.58–3.91)3.14 (133.36)3.14 (2.55)1.65 (1.31)2.21906E-301.9683E-2760–79Septic shockInfections and infestations7311.73 (9.30–14.78)11.59 (704.92)11.56 (9.17)3.53 (3.00)4.9717E-1534.4099E-15060–79Multiple organ dysfunction syndromeGeneral disorders and administration site conditions6412.00 (9.37–15.35)11.88 (635.89)11.84 (9.25)3.57 (2.98)5.8571E-1385.1953E-13560–79PancytopeniaBlood and lymphatic system disorders627.81 (6.08–10.03)7.73 (363.22)7.72 (6.01)2.95 (2.44)1.61209E-791.42992E-7660–79Drug reaction with eosinophilia and systemic symptomsSkin and subcutaneous tissue disorders5618.79 (14.43–24.46)18.62 (928.95)18.52 (14.23)4.21 (3.44)4.05272E-503.59476E-4760–79ThrombocytopeniaBlood and lymphatic system disorders533.81 (2.91–5.00)3.79 (108.93)3.79 (2.89)1.92 (1.45)6.81995E-256.0493E-2260–79Renal impairmentRenal and urinary disorders494.71 (3.56–6.24)4.68 (141.91)4.68 (3.53)2.23 (1.71)6.42027E-325.69478E-2960–79Toxic epidermal necrolysisSkin and subcutaneous tissue disorders4729.08 (21.80–38.80)28.86 (1,253.69)28.62 (21.46)4.84 (3.76)7.22132E-516.40531E-4860–79SepsisInfections and infestations443.02 (2.24–4.06)3.00 (58.91)3.00 (2.23)1.59 (1.09)4.53043E-144.0185E-1160–79BlisterSkin and subcutaneous tissue disorders417.55 (5.55–10.26)7.50 (230.66)7.49 (5.50)2.90 (2.25)1.0888E-509.65768E-4860–79EosinophiliaBlood and lymphatic system disorders3917.37 (12.67–23.82)17.26 (594.75)17.18 (12.53)4.10 (3.15)3.37786E-342.99616E-3160–79Cardiac arrestCardiac disorders384.11 (2.99–5.65)4.09 (88.69)4.08 (2.97)2.03 (1.46)2.17401E-201.92834E-1760–79Hepatic function abnormalHepatobiliary disorders388.25 (5.99–11.35)8.20 (239.80)8.18 (5.94)3.03 (2.32)4.06013E-223.60133E-1960–79Respiratory failureRespiratory, thoracic and mediastinal disorders363.57 (2.57–4.96)3.55 (66.14)3.55 (2.56)1.83 (1.26)1.51891E-151.34727E-12≥80ThrombocytopeniaBlood and lymphatic system disorders338.02 (5.68–11.32)7.89 (198.39)7.87 (5.57)2.98 (2.21)5.35592E-192.30304E-16≥80PyrexiaGeneral disorders and administration site conditions324.07 (2.87–5.78)4.02 (72.79)4.01 (2.83)2.01 (1.37)6.60408E-172.83975E-14≥80PancytopeniaBlood and lymphatic system disorders2610.12 (6.87–14.92)9.99 (209.74)9.95 (6.75)3.31 (2.34)1.16452E-175.00745E-15≥80Clostridium difficile infectionInfections and infestations2631.30 (21.20–46.21)30.86 (742.09)30.48 (20.65)4.93 (3.30)1.26887E-295.45612E-27≥80Hepatic function abnormalHepatobiliary disorders2214.13 (9.27–21.54)13.97 (263.59)13.89 (9.11)3.80 (2.55)4.10172E-181.76374E-15≥80EosinophiliaBlood and lymphatic system disorders2122.92 (14.87–35.30)22.66 (430.97)22.46 (14.58)4.49 (2.88)1.61653E-216.95108E-19≥80Renal impairmentRenal and urinary disorders214.17 (2.71–6.41)4.13 (49.90)4.13 (2.68)2.04 (1.23)7.82179E-123.36337E-09≥80Depressed level of consciousnessNervous system disorders208.81 (5.66–13.70)8.72 (136.42)8.69 (5.59)3.12 (2.03)7.1286E-133.0653E-10≥80SeizureNervous system disorders186.30 (3.96–10.03)6.25 (79.31)6.24 (3.92)2.64 (1.62)1.83571E-097.89354E-07≥80Pseudomembranous colitisInfections and infestations17,128.41 (78.67–209.60)127.21 (2,022.16)120.88 (74.06)6.92 (3.28)5.03646E-302.16568E-27≥80Septic shockInfections and infestations1711.98 (7.42–19.33)11.87 (168.58)11.82 (7.32)3.56 (2.20)3.17473E-131.36514E-10≥80Clostridium difficile colitisInfections and infestations1623.85 (14.55–39.12)23.65 (343.87)23.43 (14.29)4.55 (2.63)4.94244E-172.12525E-14≥80Drug eruptionSkin and subcutaneous tissue disorders1522.49 (13.50–37.47)22.31 (302.65)22.12 (13.27)4.47 (2.52)1.07178E-154.60865E-13≥80Clostridium test positiveInvestigations1487.84 (51.43–150.02)87.17 (1,150.98)84.16 (49.28)6.40 (2.92)9.28511E-233.9926E-20≥80EncephalopathyNervous system disorders1414.73 (8.69–24.96)14.62 (176.69)14.54 (8.58)3.86 (2.18)2.54741E-121.09539E-09 Age-stratified robust adverse event signals associated with meropenem in the FAERS database. In the 18–39-year group, pyrexia, acute kidney injury, DRESS, neutropenia, septic shock, and eosinophilia were commonly reported (Table 4), indicating that, in addition to infection-related events, immune-mediated reactions and hematologic abnormalities also deserve attention in young adults. Within the 40–59-year group, rash, acute kidney injury, DRESS, thrombocytopenia, and multiple organ dysfunction syndrome were prominent signals (Table 4). This age group displayed a mixed profile characterized by cutaneous reactions, renal injury, hematologic abnormalities, and severe systemic events (Supplementary Table 2). The 60–79-year age group had the highest number of reports. Common signals in this group included rash, acute kidney injury, septic shock, multiple organ dysfunction syndrome, and pancytopenia (Table 4). These signals were more frequently reported within this age stratum and primarily involved renal injury, infection-related events, and multiorgan dysfunction-related reports. In the ≥80-year group, thrombocytopenia, pyrexia, pancytopenia, Clostridium difficile infection, hepatic function abnormal, and eosinophilia emerged as the principal signals (Table 4). Compared with other age groups, reports of Clostridium difficile infection, hematologic abnormalities, and hepatobiliary disorders appeared relatively more prominent among patients aged ≥80 years. Age-enrichment patterns at the SOC level The SOC-level heatmap demonstrated heterogeneous distribution of robust PT signals across age groups (Figure 3A). Infections and infestations, skin and subcutaneous tissue disorders, blood and lymphatic system disorders, hepatobiliary disorders, renal and urinary disorders, and nervous system disorders contributed substantially to the signal burden across multiple age strata. Colors represent row-wise Z scores calculated from SOC-specific signal counts across age strata, thereby reflecting relative age-enrichment patterns rather than absolute signal frequencies. The PT-level heatmap further revealed age-related enrichment patterns among representative robust signals (Figure 3B). Colors represent row-wise Z scores derived from PT-specific counts across age groups, with positive values indicating relatively enriched reporting within a particular age stratum. Signals related to hypersensitivity reactions, hematologic abnormalities, renal injury, severe infections, and hepatobiliary disorders exhibited distinct age-dependent reporting patterns. For example, DRESS, anaphylactic reaction, and type IV hypersensitivity reaction were relatively enriched in younger age groups. In contrast, acute kidney injury, renal impairment, thrombocytopenia, pancytopenia, and Clostridium difficile infection were more prominent in middle-aged and older adults. These findings suggest that age-stratified analyses help identify clinically relevant differences in the spectrum of meropenem-associated adverse event reporting. For transparency, additional analyses of disease-context PTs that may be influenced by underlying infection severity, indication, or clinical status are presented in Supplementary Figures 2C, D. Although these PTs were not emphasized as core adverse event signals, age-related differences in their reporting patterns were also observed. Signals associated with serious and fatal outcomes Outcome analysis demonstrated a relatively high burden of serious outcomes among meropenem-associated reports. The proportions of serious outcomes exceeded 85% in the 40–59, 60–79, and ≥80-year groups (Figure 2B). Fatal outcome reporting proportions also increased with age and were highest in the 60–79-year group (18.1%), followed by the ≥80-year group (17.9%) and the 40–59-year group (17.3%; Figure 2A). At the SOC-level, higher fatal outcome reporting proportions were observed for neoplasms benign malignant and unspecified (including cysts and polyps), cardiac disorders, infections and infestations, general disorders and administration site conditions and surgical and medical procedures (Figure 2C). At the PT-level, toxic epidermal necrolysis, liver abscess, hepatic failure, renal failure, acute hepatic failure, Stevens–Johnson syndrome, bone marrow failure, systemic candidiasis, thrombocytopenia neonatal, Clostridium difficile colitis, acute kidney injury, and anemia were associated with relatively high fatal outcome reporting proportions (Figure 2D). PT-level analysis of serious outcome-associated signals identified drug-induced liver injury, Clostridium difficile infection, clostridium test positive, disease progression, fungal infection, toxic to various agents and confusional state as PTs associated with serious outcomes (Supplementary Figure 2F). Analysis of death-associated signals further demonstrated strong disproportionality relationships between fatal outcomes and events such as multiple organ dysfunction syndrome, bronchopulmonary aspergillosis, death, cardiac arrest, and septic shock (Supplementary Figure 2E). Importantly, as FAERS is a spontaneous reporting database, these findings reflect report-level disproportionality signals rather than true incidence rates, relative risks, or causal associations. HCP-only sensitivity analysis The HCP-restricted sensitivity analysis included 3,184 reports from healthcare professionals. Compared with the primary analysis, the ranking of commonly reported PTs remained largely consistent in the HCP-only cohort. PTs such as rash, pyrexia, acute kidney injury, thrombocytopenia, pancytopenia, seizure, DRESS, dyspnoea, pruritus, diarrhea, eosinophilia, and hepatic function abnormal remained among the most frequently reported events in both the primary and HCP-only analyses (Figure 2E). PT-level report counts showed a strong positive correlation between the primary and HCP-only analyses, with a Spearman correlation coefficient of 0.915 (P < 0.001), indicating substantial consistency between the two datasets (Figure 2F). Discussion Unlike previous studies that primarily focused on the overall safety profile of carbapenem antibiotics, the present study further examined meropenem-associated adverse events with respect to age stratification, outcome severity, time to onset and reporting-source stability. The principal findings were as follows: meropenem-associated adverse event signals were more frequently reported among patients aged 40–79 years, and a higher proportion of serious and fatal outcome reports was observed among reports submitted for patients aged ≥40 years. Most adverse events occurred during the early treatment period, suggesting that the first 10 days after treatment initiation may represent a critical window for safety monitoring. Age-stratified analyses showed that the burden of meropenem-associated signals did not increase linearly with age but was most concentrated among individuals aged 40–79 years. This finding suggests that clinical risk management should not focus exclusively on the very elderly (≥80 years) but should also pay close attention to hospitalized and critically ill patients aged >40 years, particularly those aged 40–79 years. Previous studies have indicated that the increased risk of adverse drug reactions among middle-aged and older adults is commonly associated with declining renal function, multimorbidity, polypharmacy, and reduced physiological reserve rather than age alone (21, 22). Lifespan pharmacokinetic studies have likewise suggested that meropenem dose optimization should primarily consider renal function rather than chronological age alone (23). Importantly, because age-stratified disproportionality analyses were conducted using age-specific FAERS reports as reference populations and FAERS lacks exposure denominators, these findings should be interpreted as relative reporting enrichment patterns rather than evidence of age-specific incidence or risk. Distinct adverse event profiles were observed across age groups. In pediatric and adolescent patients, immune hypersensitivity reactions, hepatobiliary abnormalities, and hematologic disorders appeared relatively prominent. In contrast, middle-aged and older adults exhibited greater burdens of acute kidney injury, hematologic abnormalities, severe infection-related events, multiorgan dysfunction, and severe cutaneous reactions. These findings indicate that age-stratified analysis is not merely a demographic description but may help identify age-specific priorities for safety surveillance. From a clinical perspective, individualized risk assessment during meropenem therapy should therefore integrate patient age, renal function, underlying diseases, and treatment context. The present study further demonstrated that serious and fatal outcomes were substantially more frequent among individuals aged ≥40 years than among younger patients. Because FAERS lacks information regarding true exposure denominators and disease severity, these findings should not be interpreted as evidence that meropenem directly increases the risk of severe outcomes. Nevertheless, from a pharmacovigilance perspective, the enrichment of serious and fatal outcomes among middle-aged and older patients remains clinically informative. Clinical monitoring should not focus solely on the most frequently reported events. Still, it should also prioritize high-risk events associated with serious or fatal outcomes, including multiple organ dysfunction syndrome, septic shock, respiratory failure, severe cutaneous adverse reactions, drug-induced liver injury, and neurologic events. Based on the present findings, clinicians may prioritize early monitoring within 10 days after meropenem initiation, particularly in patients aged ≥40 years, those with unstable renal function, and patients receiving intensive or combination antimicrobial therapy. Renal- and nervous system-related signals were among the most clinically interpretable findings of this study. Because meropenem is primarily eliminated through renal excretion, changes in renal function may directly influence drug clearance and systemic exposure. The prescribing information recommends dose adjustment in patients with renal impairment and highlights the potential risk of seizures and other central nervous system adverse reactions. Recent studies on β-lactam-associated neurotoxicity have further demonstrated that renal dysfunction, elevated drug exposure, critical illness, and underlying neurological disease may all increase the risk of neurotoxic events (24, 25). In the present study, acute kidney injury, renal impairment, seizure, confusional state, depressed level of consciousness, and encephalopathy emerged as clinically relevant signals, suggesting that renal monitoring and neurological assessment should constitute essential components of meropenem safety management. In addition, hematologic, hepatobiliary, and severe cutaneous adverse reactions deserve particular attention. Signals including thrombocytopenia, pancytopenia, neutropenia, eosinophilia, hepatic dysfunction, and drug-induced liver injury were identified in this study. Previous literature has suggested that carbapenems may be associated with platelet abnormalities (26). Although meropenem-related liver injury is considered relatively uncommon, case reports and ICU-based studies have indicated potential clinical significance (18, 27, 28). Furthermore, severe cutaneous reactions such as DRESS, toxic epidermal necrolysis (TEN), and toxic drug eruption, although not necessarily among the most frequent events, carry substantial clinical risk. The onset of β-lactam-associated DRESS may occur earlier than traditionally recognized (29), and antibiotics are recognized as important contributors to Stevens–Johnson syndrome and TEN (30, 31). Therefore, the occurrence of rash, fever, eosinophilia, hepatic dysfunction, or mucosal involvement during therapy should prompt timely evaluation for severe hypersensitivity reactions. The TTO analysis of reports with available date information demonstrated a relatively short median onset time, and the Weibull analysis suggested an early-reporting pattern within this subset, indicating that reported events with available TTO data tended to occur during the early treatment period. The Weibull model has been widely applied in pharmacovigilance studies to describe temporal reporting patterns, with a shape parameter (β) < 1 generally interpreted as an early-failure or early-reporting pattern (32, 33). Although TTO data derived from spontaneous reporting systems may be affected by missing information, reporting delays, and right truncation, and should not be interpreted as a precise biological latency period (34), the observed clustering of reports within the first 10 days after meropenem initiation suggests that this period may warrant closer clinical attention. These findings may support heightened clinical awareness of neurological manifestations, renal dysfunction, hematological abnormalities, changes in liver function, gastrointestinal symptoms suggestive of Clostridium difficile infection, and cutaneous hypersensitivity reactions during the early treatment period. However, such observations represent reporting patterns and should not be interpreted as evidence of increased incidence or causal risk in specific patient populations. Sex-stratified analysis did not reveal stable or systematic differences between males and females. Although a small number of PTs appeared relatively more prominent in one sex, the overall AE spectrum and TTO distributions were broadly comparable between sexes. Accordingly, in the present study, sex appeared to contribute less to the interpretation of meropenem-associated adverse events than age, organ function status, and temporal risk windows. Furthermore, an HCP-restricted sensitivity analysis demonstrated good agreement between the primary and healthcare professional-only analyses for high-frequency PTs and SOC distributions, with a strong PT-level correlation. These findings suggest that reports from non-healthcare professionals did not predominantly drive the principal signal structure identified in this study. Previous studies have similarly indicated that reporter type may influence reporting completeness and terminological accuracy; however, patient and consumer reports may also provide complementary safety information (35–37). The present study employed four disproportionality analysis approaches-ROR, PRR, EBGM, and IC-combined with Bonferroni correction for signal screening. The use of multiple algorithms may reduce the instability associated with reliance on any single method and thereby enhance the robustness of signal interpretation. Nevertheless, disproportionality analyses remain susceptible to repeated reporting, indication-related confounding, database structure, comparator selection, and reporting bias and therefore require cautious interpretation (38–40). Consequently, the findings of this study should be interpreted as pharmacovigilance signals derived from FAERS reporting data rather than estimates of clinical incidence or causal risk. This study has several limitations. First, as a spontaneous reporting database, FAERS is inherently subject to underreporting, duplicate reporting, selective reporting, and missing information and therefore cannot represent the true incidence of adverse events in real-world settings. Second, because FAERS lacks explicit drug exposure denominators, this study could not estimate the absolute or relative risk of meropenem-associated adverse events. Disproportionality analyses reflect report-level associations between drugs and adverse events rather than causal relationships, and may still be affected by reporting bias and database structure. In addition, meropenem is primarily prescribed for severe infections and critically ill patients, and infection severity, disease progression, organ dysfunction, and concomitant medications may all influence signal interpretation. FAERS also lacks key clinical information, including dosage, treatment duration, renal function, and detailed concomitant medication data, thereby limiting further adjustment analyses. Meropenem is primarily administered to patients with severe and life-threatening infections. Therefore, several identified signals, including sepsis, septic shock, multiple organ dysfunction syndrome, and acute kidney injury, may partly reflect the underlying disease process, infection severity, or critical illness rather than direct drug toxicity. Because FAERS lacks detailed clinical information, residual confounding by indication and disease severity cannot be excluded. Consequently, these findings should be interpreted as signals of disproportionality rather than evidence of causality. TTO analysis included only 1,371 reports with complete date information and may therefore be affected by missing dates, reporting delays, and selection bias. Likewise, age-stratified analyses were conducted only among reports containing valid age information, and their findings should therefore be interpreted as relative distribution patterns at the reporting level rather than true risk estimates. Despite these limitations, the present study leveraged large-scale real-world pharmacovigilance data to provide valuable evidence on the adverse event spectrum of meropenem and its age-related heterogeneity; these findings warrant further validation through clinical and prospective studies. Conclusions Meropenem-associated disproportionality signals involved multiple system organ classes and showed heterogeneous age-stratified reporting patterns and temporal characteristics. Signal reports were more frequently distributed among patients aged 40–79 years, while higher proportions of reported serious and fatal outcomes were observed among patients aged ≥40 years. TTO and Weibull analyses suggested an early-reporting pattern among reports with available date information. Collectively, these findings support age-stratified signal interpretation and early clinical monitoring as complementary components of meropenem pharmacovigilance, while emphasizing that FAERS-based signals represent reporting associations rather than causal evidence.